The American Action Forum published a policy insight that suggested 340B providers could avoid IRA-negotiated lower-cost drugs.
Group Critical of Medicare Negotiation and 340B Program Suggests 340B Providers May Avoid IRA Negotiated Lower-Cost Drugs
Views
Medicare Part D plans and 340B providers may avoid drugs with negotiated lower Medicare prices to maximize revenue from rebates, [...]
Please Login or Become a Paid Subscriber to View this Content
If you are already a paid subscriber, please follow the steps below.
